SCHEMBL19965112

SCHEMBL19965112

O=C1c2cccc(Br)c2CN1c1ccnc(Oc2cccnc2)n1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.36
CYP11B2 P19099 1/20 0.36
LMNA P02545 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
CBLB Q13191 1/20 0.33
DHPS P49366 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
UGCG Q16739 2/20 0.33
ALDH1A1 P00352 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAP3K5 Q99683 3/20 0.33
IDH1 O75874 1/20 0.33
HTT P42858 2/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19965120 0.84 SMN1; SMN2 (0.46) FFAR4CYP11B2LMNATDP1MKNK1
SCHEMBL19965197 0.84 CYP11B2 (0.54) FFAR4CYP11B2MKNK1CBLBMAP3K5
SCHEMBL19965013 0.78 CYP11B2 (0.43) CYP11B2MAP3K5
SCHEMBL19965178 0.78 PRKCA (0.46) CYP11B2MAP3K5MAPK1
SCHEMBL19965003 0.78 CYP11B2 (0.38) FFAR4CYP11B2LMNATDP1MKNK1
SCHEMBL19965113 0.75 TRPV1 (0.41) CBLBCDK5CDK5R1UGCGMAP3K5
SCHEMBL19965052 0.70 CYP11B2 (0.56) FFAR4CYP11B2MAP3K5
SCHEMBL19965105 0.70 HRH4 (0.42) FFAR4CYP11B2LMNATDP1MKNK1
SCHEMBL21123972 0.67 FFAR4 (0.44) FFAR4LMNATDP1MKNK1ALDH1A1
SCHEMBL19965076 0.66 MKNK1 (0.35) LMNATDP1MKNK1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2023-06-15 US disclosed
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS Valo Health, LLC 2023-06-15 US disclosed
WO-2018049324-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS NUMERATE, INC. (US) 2018-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183231-A1 MONOCYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 FFAR4 32/4885CYP11B2 571/4885LMNA 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.